EBMT 2022 | Targeting the lectin pathway in HSCT-TMA
Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, talks on the role of the lectin pathway in hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA), highlighting is potential as a therapeutic target. The lectin pathway plays an important role in the complement pathway. MASP-2, a component of this pathway, has emerged as a promising target for the treatment of HSCT-TMA and narsoplimab is currently under investigation for approval by the FDA. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Dr Gavriilaki has served as a consultant and/or received honoraria from Alexion Pharmaceuticals, Omeros Corporation, and Sanofi. Dr Gavriilaki has received research support from Jazz Pharmaceuticals.
